Publication Type : Journal Article
Source : World Journal of Gastroenterology. 2022 Sep 28;28(36):5250-5264. doi: 10.3748/wjg.v28.i36.5250. PMID: 36185626; PMCID: PMC9521521.
Url : https://pubmed.ncbi.nlm.nih.gov/36185626/
Campus : Kochi
School : School of Pharmacy
Department : Pharmacognosy
Year : 2022
Abstract : Transforming growth factor-beta (TGF-β) is a multifunctional cytokine that performs a dual role as a tumor suppressor and tumor promoter during cancer progression. Among different ligands of the TGF-β family, TGF-β1 modulates most of its biological outcomes. Despite the abundant expression of TGF-β1 in the liver, steatosis to hepatocellular carcinoma (HCC) progression triggers elevated TGF-β1 levels, contributing to poor prognosis and survival. Additionally, elevated TGF-β1 levels in the tumor microenvironment create an immunosuppressive stage via various mechanisms. TGF-β1 has a prime role as a diagnostic and prognostic biomarker in HCC. Moreover, TGF-β1 is widely studied as a therapeutic target either as monotherapy or combined with immune checkpoint inhibitors. This review provides clinical relevance and up-to-date information regarding the potential of TGF-β1 in diagnosis, prognosis, and therapy against HCC.
Cite this Research Publication : Devan AR, Pavithran K, Nair B, Murali M, Nath LR. Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma. World Journal of Gastroenterology. 2022 Sep 28;28(36):5250-5264. doi: 10.3748/wjg.v28.i36.5250. PMID: 36185626; PMCID: PMC9521521.